DAVID ROSS CAMIDGE, MD, PHD, of University of Colorado Denver discusses the role of T790M mutations in resistance to first generation EGFR TKIs and what role agents such as Rociletinib may have in the future.
DAVID ROSS CAMIDGE, MD, PHD, of University of Colorado Denver discusses the role of T790M mutations in resistance to first generation EGFR TKIs and what role agents such as Rociletinib may have in the future.